Company profile: Senti Bio
1.1 - Company Overview
Company description
- Provider of synthetic biology-driven cell and gene therapies for cancer, featuring a Gene Circuit platform to program therapies, off-the-shelf CAR-NK cell therapies, and investigational candidates SENTI-202 (logic-gated targeting of CD33/FLT3 for hematologic malignancies incl. AML) and SENTI-301A (for GPC3+ tumors with crIL-15 Gene Circuit), with manufacturing via GeneFab.
Products and services
- Gene Circuit Technology: Proprietary DNA-sequence synthetic biology platform that programs cell and gene therapies to target diseased cells while sparing healthy tissue for cancer treatment
- SENTI-202: Logic-gated CAR-NK cell therapy for hematologic malignancies, including AML, targeting CD33 and/or FLT3 via Gene Circuits to achieve enhanced selectivity
- CAR-NK Cell Therapy: Off-the-shelf chimeric antigen receptor natural killer cells engineered with Gene Circuit Technology to enhance tumor targeting and efficacy in cancer settings
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Senti Bio
Genelex
HQ: United States
Website
- Description: Provider of pharmacogenetic testing for precision medication management, backed by innovative analytics software, state-of-the-art laboratory facilities, and expert staff; a pioneer in DNA testing since 1987.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genelex company profile →
Tocris Bioscience
HQ: United Kingdom
Website
- Description: Provider of reagents for non-clinical life science research, including TR-FRET donors (CoraFluor 2) for assay development and biomolecule labeling; selective HDAC3 degraders (JPS036) for targeted protein degradation; M5 receptor antagonists (VU 6019650); dual LAG3 interaction inhibitors (SA-15-P) for immune checkpoint research; ALDH detection substrates (BAAA-DA); and near-infrared fluorogens (SiRA 2) for RNA imaging.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tocris Bioscience company profile →
GeneInsight
HQ: United States
Website
- Description: Provider of an IT platform that streamlines data interpretation and management; GeneInsight Suite has been in clinical use and evolving since 2005, developed at Partners HealthCare in collaboration with leading geneticists, laboratory operations personnel, practicing physicians, and IT professionals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneInsight company profile →
Actogenix
HQ: Belgium
Website
- Description: Provider of biopharmaceutical development and commercialization of a new generation of biological drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Actogenix company profile →
Raptor Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics, engaging in discovery, research and preclinical development of drug candidates and drug-targeting platforms for brain and neurodegenerative diseases, genetic disorders and cancer, and commercializing TEPEZZA for Thyroid Eye Disease and UPLIZNA for neuromyelitis optica spectrum disorder in AQP4 antibody-positive adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Raptor Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Senti Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Senti Bio
2.2 - Growth funds investing in similar companies to Senti Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Senti Bio
4.2 - Public trading comparable groups for Senti Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →